A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Leukemia and Lymphoma

• Publication date

  2015-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2015.1030638PMID 25797560PMCID PMC4643417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• a inhibitor

  2017cited by this paper
• PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263.

  2016cited by this paper
• The role of apoptosis in megakaryocytes and platelets

  2014cited by this paper
• The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199

  2014cited by this paper
• Apoptosis deregulation in CLL.

  2013cited by this paper
• Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• BH3 Mimetics: Status of the Field and New Developments

  2013cited by this paper
• Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis

  2013cited by this paper
• Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

  2012cited by this paper
• Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo

  2012cited by this paper
• Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy.

  2012cited by this paper
• Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.

  2011cited by this paper
• An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

  2011cited by this paper
• Patient flow diagram

  2011cited by this paper
• The spectrum of use of rituximab in chronic lymphocytic leukemia

  2010cited by this paper
• A practical guide to understanding Kaplan-Meier curves

  2010cited by this paper
• Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice.

  2010cited by this paper
• The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

  2010cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• Guidelines for

  2007cited by this paper
• Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.

  2005cited by this paper
• inhibitor of

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2003cited by this paper
• bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow.

  2003cited by this paper
• Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

  2000cited by this paper
• COIL-GLOBULE TRANSITION OF A SEMIFLEXIBLE POLYMER DRIVEN BY THE ADDITION OF SPHERICAL PARTICLES

  1997cited by this paper
• The Eastern Cooperative Oncology Group

  1994cited by this paper
• Population pharmacokinetics.

  1992cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

  1981cited by this paper

• Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption

  2026cites this paper
• Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.

  2026cites this paper
• BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting

  2026cites this paper
• Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas.

  2026cites this paper
• Platelet aging and desialylation increase apoptotic priming and BCL-XL dependence

  2026cites this paper
• The Role of Senescence, its Therapeutic Relevance and Clinical Implications in the Tumor Microenvironment

  2025cites this paper
• Pharmacological frontiers in senescence: Transforming senescence with drug repurposing.

  2025cites this paper
• Harnessing the interaction between redox signaling and senescence to restrain tumor drug resistance

  2025cites this paper
• The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

  2025cites this paper
• Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy.

  2025cites this paper
• Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

  2025cites this paper
• The crosstalk between senescence, tumor, and immunity: molecular mechanism and therapeutic opportunities

  2025cites this paper
• Emerging prodrug and nano-drug delivery strategies for the detection and elimination of senescent tumor cells.

  2025cites this paper
• Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263

  2025cites this paper
• Zinc(II)-berberine-based complexes targeting mitochondria exhibit enhanced antiproliferative activity as single drugs or in combination with ABT-199.

  2025cites this paper
• Endoplasmic Reticulum Stress–Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells

  2025cites this paper
• Senescent Cancer Cells in Immune Surveillance and Evasion: Mechanisms and Therapeutic Implications.

  2025cites this paper
• Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges

  2024cites this paper
• Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy

  2024influential citation
• Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis

  2024cites this paper
• Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment.

  2024cites this paper
• Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models

  2024cites this paper
• BCL-XL–targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors

  2024cites this paper
• Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials

  2024cites this paper
• Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family.

  2024cites this paper
• LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia

  2024cites this paper
• Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies

  2024cites this paper
• The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment.

  2024cites this paper
• Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer

  2024cites this paper
• AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death

  2024cites this paper
• Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.

  2024cites this paper
• Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.

  2024cites this paper
• Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer.

  2023cites this paper
• Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

  2023cites this paper
• Targeting MCL-1 protein to treat cancer: opportunities and challenges

  2023cites this paper
• Silencing of the MEG3 gene promoted anti‐cancer activity and drug sensitivity in glioma

  2023cites this paper
• The Emerging Role of Senotherapy in Cancer: A Comprehensive Review

  2023cites this paper
• RHNO1 disruption inhibits cell proliferation and induces mitochondrial apoptosis via PI3K/Akt pathway in hepatocellular carcinoma.

  2023cites this paper
• The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells

  2023cites this paper
• Understanding and targeting resistance mechanisms in cancer

  2023cites this paper
• Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells

  2023cites this paper
• Topical Administration of an Apoptosis Inducer Mitigates Bleomycin-Induced Skin Fibrosis.

  2023cites this paper
• Research Progress of Venetoclax in the Treatment of HematologicMalignancies

  2023cites this paper
• Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases

  2023cites this paper
• Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy

  2022cites this paper
• Obesity triggers tumoral senescence and renders poorly immunogenic malignancies amenable to senolysis

  2022cites this paper
• Modeling of Anticancer Sulfonamide Derivatives Lipophilicity by Chemometric and Quantitative Structure-Retention Relationships Approaches

  2022cites this paper
• Silencing of MEG3 gene promoted anti-cancer activity and drug sensitivity in glioma

  2022cites this paper
• Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy.

  2022cites this paper
• The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

  2022cites this paper
• Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis in vitro and represses tumour growth in an in vivo xenograft model

  2022cites this paper
• Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

  2022influential citation
• Therapeutics targeting BCL2 family proteins

  2022cites this paper
• Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy.

  2022cites this paper
• Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

  2022cites this paper
• Exploiting senescence for the treatment of cancer

  2022cites this paper
• Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells

  2021cites this paper
• Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model.

  2021cites this paper
• Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy

  2021cites this paper
• Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

  2021cites this paper
• The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy.

  2021cites this paper
• Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies

  2021cites this paper
• A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions

  2021cites this paper
• Therapeutics Targeting the Core Apoptotic Machinery

  2021influential citation
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis

  2021cites this paper
• Chemogenomics for drug discovery: clinical molecules from open access chemical probes

  2021cites this paper
• A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.

  2021cites this paper
• The Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells

  2021cites this paper
• From Apoptosis to Necroptosis: The Death Wishes to Cancer

  2021cites this paper
• Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies

  2021influential citation
• Utility of circulating microRNA-150 for rapid evaluation of bone marrow depletion after radiation, and efficiency of bone marrow reconstitution.

  2021cites this paper
• Senolytics: A Novel Strategy for Neuroprotection in ALS?

  2021cites this paper
• BH3-mimetics: recent developments in cancer therapy

  2021cites this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cites this paper
• Mechanism of interaction between autophagy and apoptosis in cancer

  2021cites this paper
• Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma

  2021cites this paper
• BCL2 inhibitors and MCL1 inhibitors for hematological malignancies.

  2021cites this paper
• Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation

  2020cites this paper
• Apoptosis and Cancer

  2020cites this paper
• BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells

  2020cites this paper
• Cell Death Pathways in Lymphoid Malignancies

  2020cites this paper
• Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm

  2020cites this paper
• Targeting apoptosis in cancer therapy

  2020cites this paper
• Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature.

  2020cites this paper
• BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas

  2020cites this paper
• Investigating the response of paediatric leukaemia‐propagating cells to BCL‐2 inhibitors

  2020cites this paper
• Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

  2020cites this paper
• Enhancing venetoclax activity in hematological malignancies

  2020cites this paper
• DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity

  2020cites this paper
• The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia

  2020cites this paper
• Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies

  2020cites this paper
• Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.

  2020cites this paper
• IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.

  2020cites this paper
• Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent

  2020cites this paper
• Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study

  2020cites this paper
• Development of Mcl-1 inhibitors for cancer therapy.

  2020cites this paper
• Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

  2020cites this paper
• Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro

  2020cites this paper
• Venetoclax for the Treatment of Chronic Lymphocytic Leukemia

  2019cites this paper